A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Inclusion Criteria:

1. Participant must be at least 18 years of age, inclusive, at the time of signing theICF.

2. Histologically confirmed diagnosis of classic FL per WHO 2022 classification

3. ECOG performance status of 0 to 2

4. No prior systemic lymphoma-directed therapy

5. Need for systemic treatment meeting at least 1 GELF criteria

6. FDG-avid and measurable disease

7. Stage II to IV and FLIPI 2-5 [Phase III only]

8. Adequate liver, hematological, renal and cardiac function.

The above is a summary, other inclusion criteria details may apply

Exclusion Criteria:

1. Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicularlymphoma Grade 3B (WHO 2016 classification) or suspicion for histologictransformation to high-grade/aggressive lymphoma

2. Contra-indication to BR, RCVP, and R-CHOP

3. Participants with or history of CNS lymphoma

4. History of a clinically relevant CNS medical condition or pathology that requiredtreatment in the preceding year, is currently symptomatic or that which the treatinginvestigator considers to have the potential to interfere with the evaluation ofsafety

5. Presence of >5000 circulating lymphoma cells

6. Active or uncontrolled infection (including EBV) requiring systemic therapy andwhich places participant at unacceptable risk if he/she were to participate in thestudy. If a participant has a history of COVID-19 within 1 month of C1D1 orcontracts COVID while on study treatment, participant must have 2 consecutivenegative tests (PCR testing is preferable) performed at least 48 hours apart priorto resuming dosing. All symptoms related to COVID-19 infection should have fullyresolved before initiating or resuming treatment

7. Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

The above is a summary, other exclusion criteria details may apply